Skip to main content

Table 1 Characteristics of 96 cancer patients with neuropathic pain

From: Lidocaine transdermal patches reduced pain intensity in neuropathic cancer patients already receiving opioid treatment

Characteristics

Number (%)

Patient No.

96 (100)

Age (years)

 Median age, yr (Range)

58 (20-96)

Performance Status

 1-2

20 (20.8)

 3-4

76 (75.2)

Sex

 Male/Female

50/46 (58.3/41.7)

Diagnosis

 HNSCC

15 (15.6)

 UGI Cancer

14 (14.6)

 Colorectal Cancer

12 (12.5)

 GU Cancer

10 (10.4)

 Lung Cancer

10 (10.4)

 Breast Cancer

9 (9.4)

 HCC

9 (9.4)

 GYN Cancer

6 (6.3)

 Thyroid Cancer

6 (6.3)

 Sarcoma

3 (4.1)

 Lymphoma

1 (1.0)

 MUO

1 (1.0)

Concurrent analgesic regimen

 Opioids

96 (100)

 NSAID

15 (15.6)

 Acetaminophen

15 (15.6)

 Corticosteroid

14 (14.6)

 Antidepressants

7 (7.3)

Pain score at rest (NRS)

 0-3

39 (40.6)

 4-7

50 (52.1)

 8-10

7 (7.3)

Pain score on movement (NRS)

 0-3

8 (8.3)

 4-7

53 (55.2)

 8-10

35 (36.5)

Applied Sites

 Torso

52 (54.2)

 Legs

20 (20.8)

 Head and Neck

18 (18.8)

 Arms

5 (5.2)

 Hands

1 (1.0)

Sensory Dysfunction

 Allodynia

52 (54.2)

 Raised Pin-Prick Threshold

45 (46.9)

 Hyperalgesia

31 (32.3)

 Tingling

34 (35.4)

 Pinprick

30 (31.3)

 Stabbing

28 (29.2)

 Numbness

26 (27.1)

 Tight/stretched

33 (34.3)

 Burning

20 (20.8)

 Cutting/Laceration

28 (29.2)

  1. Abbreviations: HNSCC Head and neck squamous cell carcinoma, UGI upper gastrointestinal, GU genitourinary, HCC hepatocellular carcinoma, GYN gynecological, MUO malignancy of unknown origin, NRS numerical rating scale